TARGET RESEARCH ARTICLES
-
Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar
Discovery on Target 2026 showed how new modalities and AI are expanding drug discovery as investors demand stronger data and clearer paths to value.
-
Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics
Stacy Blain, PhD, turned 30 years of p27 research into Concarlo’s LOCKTAC, a molecular glue designed to restore natural CDK2/4/6 inhibition in cancer.
-
Viewing Treatment Resistance As A Target
Viewing treatment resistance as a target instead of an undesirable side effect could allow effective treatments to work for longer.
-
Target Transcription Factor States, Not Pockets
Transcription factors expose broad protein–DNA and protein–protein interfaces, contain intrinsically disordered regions, and exchange partners as cellular context changes.
-
Beyond Apoptosis: Context Is The Target
Cells that evade apoptosis do not necessarily evade death; they may remain vulnerable to ferroptosis, pyroptosis, necroptosis, or another regulated cell death program.
-
Alpha-Synuclein Is Not One Target
Alpha-synuclein is not one target, and a nanobody is not a smaller antibody with automatic access.
TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
Discover how EPR complements structural maps by resolving flexible regions, detecting hidden conformational states, identifying differences between grid-based and solution conditions, and revealing the dynamic changes that connect molecular structure with biological function.
-
Explore a scalable RNA-seq approach that delivers reproducible, high-quality transcriptomic data from checkpoint-edited T-cells, uncovering gene expression changes linked to PD-1 and TIGIT deletion.
-
Discover how automated EPR pulsed dipolar spectroscopy measures protein dynamics, complements Cryo-EM and AlphaFold, and delivers crucial structural insights for drug discovery.
-
Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.
-
Resolving dynamic states in membrane proteins is vital for drug discovery. EPR spectroscopy tracks conformational shifts in native environments, bypassing standard structural limits.
-
Repeat dosing may be essential for long-term mRNA applications. Explore safety, immune-response, and efficacy findings from multiple LNP administrations, including a nine-dose evaluation over six months.
TARGET RESEARCH SOLUTIONS
-
Capturing dynamic conformational states is key to target druggability. Advanced EPR spectroscopy delivers nanometer-resolution measurements for complex structural biology.
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record.
-
HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency.
-
The demand for high-throughput antibodies has exponentially increased over the last couple of years and has rapidly accelerated the antibody screening process.
-
E. coli is often the system of choice for biomanufacturing because of its amenability to genetic manipulation, low production cost, and rapid timelines for bioexpression.
-
Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns
-
We deliver custom assay development, screening, potency, and selectivity testing services for the pharmaceutical, biopharmaceutical, and agrochemical industries.
-
Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Curia’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customizable solutions.
-
At Curia, our team of expert protein chemists and structural biologists brings the advanced experience and technology needed to support all your structural biology services needs.
-
High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.
-
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.